Last reviewed · How we verify
ILUMYA (TILDRAKIZUMAB-ASMN)
ILUMYA (generic name: TILDRAKIZUMAB-ASMN) is a Interleukin-23 Antagonist [EPC] drug developed by SUN PHARMA GLOBAL. It is currently FDA-approved for Plaque psoriasis.
ILUMYA is a monoclonal antibody that targets Interleukin-23, classified as an inhibitor. It is used to treat conditions such as Psoriasis Vulgaris, Plaque-type Psoriasis, and Moderate to Severe Nail Psoriasis.
At a glance
| Generic name | TILDRAKIZUMAB-ASMN |
|---|---|
| Sponsor | SUN PHARMA GLOBAL |
| Drug class | Interleukin-23 Antagonist [EPC] |
| Target | Interleukin-23 |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Plaque psoriasis
Common side effects
- Upper respiratory infections
- Injection site reactions
- Diarrhea
- Dizziness
- Pain in extremity
Serious adverse events
- Angioedema
- Urticaria
Key clinical trials
- ACTION: Phase I/II Trial of Abiraterone Acetate in Combination With Tildrakizumab (Anti-IL23 Targeting Monoclonal Antibody) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (Phase 1)
- A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional L (Phase 3)
- Pharmacogenetic Observational Study Evaluating the Influence of Genetic Variants and Cardiometabolic Risk Factors on 10-Year Survival of Biologic Therapies in Patients With Cutaneous Psoriasis With or (N/A)
- Effects of Tildrakizumab (ILUMYA) Use on Epigenetic Age Acceleration and Psoriasis (Phase 4)
- A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab. (Phase 2)
- A Phase IV Interventional Study to Assess the Disease-Modifying Effect of Long-Term Treatment With Tildrakizumab in Adult Patients With Moderate-To-Severe Plaque Psoriasis (MODIFY) (Phase 4)
- Investigating the Mechanisms of Short- and Long-term Responses to IL-23 Inhibition Using Tildrakizumab in Moderate to Severe Plaque Psoriasis Using High-definition Multiomics (N/A)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ILUMYA CI brief — competitive landscape report
- ILUMYA updates RSS · CI watch RSS
- SUN PHARMA GLOBAL portfolio CI
Frequently asked questions about ILUMYA
What is ILUMYA?
ILUMYA (TILDRAKIZUMAB-ASMN) is a Interleukin-23 Antagonist [EPC] drug developed by SUN PHARMA GLOBAL, indicated for Plaque psoriasis.
What is ILUMYA used for?
ILUMYA is indicated for Plaque psoriasis.
Who makes ILUMYA?
ILUMYA is developed and marketed by SUN PHARMA GLOBAL (see full SUN PHARMA GLOBAL pipeline at /company/sun-pharma-global).
What is the generic name of ILUMYA?
TILDRAKIZUMAB-ASMN is the generic (nonproprietary) name of ILUMYA.
What drug class is ILUMYA in?
ILUMYA belongs to the Interleukin-23 Antagonist [EPC] class. See all Interleukin-23 Antagonist [EPC] drugs at /class/interleukin-23-antagonist-epc.
What development phase is ILUMYA in?
ILUMYA is FDA-approved (marketed).
What are the side effects of ILUMYA?
Common side effects of ILUMYA include Upper respiratory infections, Injection site reactions, Diarrhea, Dizziness, Pain in extremity. Serious adverse events: Angioedema, Urticaria.
What does ILUMYA target?
ILUMYA targets Interleukin-23 and is a Interleukin-23 Antagonist [EPC].
Related
- Drug class: All Interleukin-23 Antagonist [EPC] drugs
- Target: All drugs targeting Interleukin-23
- Manufacturer: SUN PHARMA GLOBAL — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Plaque psoriasis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing